Doctors warn a silent liver disease now affects one in three American adults

A condition that produces few if any symptoms in its early stages has quietly become one of the most common chronic diseases in the United States, with fat building up in the livers of a large share of the adult population. Once dismissed as a benign consequence of extra weight, this so-called silent liver disease is now understood to be a serious health concern that can progress to inflammation, scarring and, in some cases, liver failure or cancer. Health authorities estimate it affects roughly a third of American adults, a prevalence that has reshaped how doctors think about liver health.

A disease renamed to reflect its causes

For decades the condition was known as nonalcoholic fatty liver disease, a label defined largely by what it was not: liver fat in people who did not drink heavily. More recently, medical bodies have moved toward new terminology, describing it as metabolic dysfunction-associated steatotic liver disease, or MASLD, to emphasize its ties to metabolic health rather than simply the absence of alcohol.

The shift is more than semantic. It reflects a growing understanding that the buildup of fat in the liver is bound up with the same metabolic problems that drive type 2 diabetes and heart disease, including obesity, insulin resistance, high blood pressure and abnormal cholesterol. Framing the disease around metabolic dysfunction points both patients and clinicians toward the underlying drivers that can be addressed.

How fat accumulates in the liver

In a healthy liver, only a small amount of fat is present. The disease begins when fat accumulates in liver cells beyond that normal level, a state known as steatosis. In many people the condition stops there and causes no lasting harm, but in a subset the fat triggers inflammation and cell injury, a more aggressive form once called nonalcoholic steatohepatitis, or NASH, and now often termed metabolic dysfunction-associated steatohepatitis, or MASH.

When that inflammation persists, the liver responds by laying down scar tissue in a process called fibrosis. Advanced scarring can progress to cirrhosis, in which the organ becomes so damaged that its function is compromised, raising the risk of liver failure and liver cancer. Because the early stages produce so few warning signs, the disease often advances silently until significant damage has already occurred. The National Institute of Diabetes and Digestive and Kidney Diseases describes this spectrum of fatty liver disease and the progression from simple fat buildup to more serious injury.

Why the numbers are so high

The estimate that fatty liver disease affects roughly a third of American adults tracks closely with the rise of the metabolic conditions that fuel it. As rates of obesity and type 2 diabetes have climbed, so has the prevalence of excess liver fat, since the same dietary patterns, sedentary habits and metabolic disturbances that drive those conditions also load the liver with fat.

The disease is especially common among people with diabetes and those carrying excess weight around the midsection, though it can occur in people who are not obese. Its silent nature means many of those affected are unaware they have it, often discovering the problem only when abnormal liver enzymes turn up in a routine blood test or when imaging done for another reason reveals a fatty liver.

Detecting a condition with few symptoms

Because MASLD rarely announces itself, diagnosis usually begins incidentally. Elevated liver enzymes on standard blood work can prompt further investigation, and imaging such as ultrasound can reveal fat in the liver. To gauge how much scarring has developed, doctors increasingly rely on specialized techniques that measure liver stiffness without surgery, reserving the more invasive liver biopsy for cases where the diagnosis or severity remains unclear.

Distinguishing simple fat buildup from the inflammatory, scarring form is central to care, because the outlook differs sharply between the two. Identifying those with advancing fibrosis allows clinicians to focus monitoring and treatment on the patients at greatest risk of serious complications, while reassuring those whose disease is unlikely to progress.

Turning the disease around

For most people, the cornerstone of treatment is not a pill but a change in the metabolic conditions underlying the disease. Gradual, sustained weight loss achieved through diet and physical activity can reduce liver fat, calm inflammation and even reverse some scarring in earlier stages. Managing diabetes, blood pressure and cholesterol addresses both the liver and the cardiovascular risks that often accompany it.

The landscape is also shifting on the pharmaceutical front, as researchers pursue and begin to approve medications aimed specifically at the inflammatory, scarring form of the disease. Some drugs developed for diabetes and weight management have shown benefit for the liver as well, and dedicated therapies for advanced disease have started to emerge. Even so, lifestyle change remains the foundation, and avoiding excess alcohol and unnecessary strain on the liver remains part of standard advice.

A public health priority coming into focus

The scale of the problem has pushed fatty liver disease from a quiet clinical footnote toward a recognized public health concern. With so much of the adult population affected, even a small fraction progressing to advanced disease translates into a substantial burden of cirrhosis, liver cancer and transplants, alongside the heart disease that so often travels with it.

That recognition is prompting greater emphasis on earlier detection, on identifying which patients face the highest risk, and on addressing the metabolic conditions that feed the disease across the population. Because the same habits that protect the liver also guard against diabetes and cardiovascular disease, efforts to confront this silent epidemic overlap broadly with the wider goal of improving metabolic health in a country where such conditions have become common.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview